- Home
- RNAZ vs BDRX Comparison
RNAZ vs BDRX Comparison
Compare RNAZ & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- BDRX
- Stock Information
- Founded
- RNAZ 2016
- BDRX 2000
- Country
- RNAZ United States
- BDRX United Kingdom
- Employees
- RNAZ N/A
- BDRX N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- BDRX Health Care
- Exchange
- RNAZ Nasdaq
- BDRX Nasdaq
- Market Cap
- RNAZ 6.1M
- BDRX 5.8M
- IPO Year
- RNAZ 2021
- BDRX N/A
- Fundamental
- Price
- RNAZ $7.97
- BDRX $0.90
- Analyst Decision
- RNAZ Strong Buy
- BDRX
- Analyst Count
- RNAZ 1
- BDRX 0
- Target Price
- RNAZ $280.00
- BDRX N/A
- AVG Volume (30 Days)
- RNAZ 32.8K
- BDRX 3.2M
- Earning Date
- RNAZ 08-13-2025
- BDRX 04-11-2025
- Dividend Yield
- RNAZ N/A
- BDRX N/A
- EPS Growth
- RNAZ N/A
- BDRX N/A
- EPS
- RNAZ N/A
- BDRX N/A
- Revenue
- RNAZ N/A
- BDRX N/A
- Revenue This Year
- RNAZ N/A
- BDRX N/A
- Revenue Next Year
- RNAZ N/A
- BDRX N/A
- P/E Ratio
- RNAZ N/A
- BDRX N/A
- Revenue Growth
- RNAZ N/A
- BDRX N/A
- 52 Week Low
- RNAZ $6.15
- BDRX $0.78
- 52 Week High
- RNAZ $970.20
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- RNAZ 47.04
- BDRX 39.25
- Support Level
- RNAZ $7.32
- BDRX $0.85
- Resistance Level
- RNAZ $8.48
- BDRX $0.97
- Average True Range (ATR)
- RNAZ 0.58
- BDRX 0.11
- MACD
- RNAZ 0.41
- BDRX -0.00
- Stochastic Oscillator
- RNAZ 70.77
- BDRX 28.24
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.